dynorphins and Paraplegia

Despite many advances, our understanding of the involvement of prodynorphin systems in the development of neuropathic pain is not fully understood. Recent studies suggest an important role of neuro-glial interactions in the dynorphin effects associated with neuropathic pain conditions. Our studies show that minocycline reduced prodynorphin mRNA levels that were previously elevated in the spinal and/or dorsal root ganglia (DRG) following sciatic nerve injury. The repeated intrathecal administration of minocycline enhanced the analgesic effects of low-dose dynorphin (0.15 nmol) and U50,488H (25-100 nmol) and prevented the development of flaccid paralysis following high-dose dynorphin administration (15 nmol), suggesting a neuroprotective effect. Minocycline reverts the expression of IL-1β and IL-6 mRNA within the spinal cord and IL-1β mRNA in DRG, which was elevated following intrathecal administration of dynorphin (15 nmol). These results suggest an important role of these proinflammatory cytokines in the development of the neurotoxic effects of dynorphin. Similar to minocycline, a selective inhibitor of MMP-9 (MMP-9 levels are reduced by minocycline) exerts an analgesic effect in behavioral studies, and its administration prevents the occurrence of flaccid paralysis caused by high-dose dynorphin administration (15 nmol). In conclusion, our results underline the importance of neuro-glial interactions as evidenced by the involvement of IL-1β and IL-6 and the minocycline effect in dynorphin-induced toxicity, which suggests that drugs that alter the prodynorphin system could be used to better control neuropathic pain.

Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Disease Models, Animal; Dynorphins; Ganglia, Spinal; Injections, Spinal; Interleukin-1beta; Interleukin-6; Male; Matrix Metalloproteinase 9; Minocycline; Neuralgia; Neuroprotective Agents; Paraplegia; Rats, Wistar; RNA, Messenger; Sciatic Neuropathy; Spinal Cord

To investigate the different role of neuronal constitutive nitric oxide synthase (nc-NOS) in dynorphin (Dyn) A(1-17) spinal neurotoxicity and analgesia.. The cNOS activity in ventral and dorsal spinal cord in rats was measured with H-L-arginine conversion, and ncNOS immunoreactivity(IR) was observed with strepavidin-peroxidase immunohisto-chemistry.. Intrathecal administration of Dyn A(1-17) produced dose-dependent paralysis of hindlimbs and tail as well as inhibition of tail flick (TF) and foot flinch (FF) reflexes. Dyn A(1-17) 10 nmol induced only transient paralysis and apparently reduced the ncNOS-IR in the superficial dorsal horn but did not induce any change of ncNOS-IR in the ventral horn cells as compared with saline control. Dyn A(1-17) 20 nmol produced permanent paraplegia with irreversible spinal cord damage, characterized by central and progressive necrosis. Dyn A(1-17) 20 nmol remarkedly induced the expression of ncNOS-IR in the ventral horn cells whereas inhibited ncNOS-IR in the superficial dorsal horn. Dyn A(1-17) 20 nmol also significantly increased the activities of cNOS in the ventral spinal cord but did not affect cNOS activities in the dorsal spinal cord. Intrathecal pretreatment with 7-nitroindazole (7-NI) 1 mumol, a selective ncNOS inhibitor 10 min prior to i.t. Dyn A(1-17) 20 nmol significantly ameliorated Dyn-induced neurological outcome, but TF and FF remained inhibited. 7-nitroindazole also significantly antagonized the increases of cNOS activities and ncNOS-IR in the ventral spinal cord at 4 h after i.t. Dyn A(1-17) 20 nmol, but did not affect or even potentiated Dyn-induced inhibition of cNOS activity and ncNOS-IR in the dorsal spinal cord.. Over-expression or over-activation of ncNOS in the ventral spinal cord may be involved in Dyn spinal neurotoxicity, whereas as the reduction of ncNOS activities in the dorsal spinal cord might reflect Dyn spinal analgeisia or pain modulation.

Topics: Analgesics; Animals; Dynorphins; Female; Indazoles; Male; Nerve Tissue Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pain Threshold; Paraplegia; Rats; Rats, Wistar; Spinal Cord

Opiate antagonists, at high doses, have been shown to improve physiological variables and outcome after experimental spinal injury. Dynorphin appears to be unique amongst opioids in producing hindlimb paralysis after intrathecal injection. Taken together, these findings suggest a possible pathophysiological role for endogenous opioids, particularly dynorphin, in spinal injury. In the present studies we examined the relationship between changes in dynorphin immunoreactivity (Dyn-ir) in rat spinal cord after traumatic injury and the subsequent motor dysfunction. Trauma was associated with significantly increased Dyn-ir at the injury site, but not distant from the lesion. Dyn-ir was found elevated as early as 2 h and as late as 2 weeks after trauma, and was significantly correlated with the degree of injury. These data are consistent with the hypothesis that dynorphin systems may be involved in the secondary injury that follows spinal trauma.

Topics: Animals; Dynorphins; Male; Naloxone; Narcotic Antagonists; Paraplegia; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Spinal Cord; Spinal Cord Injuries

Endogenous opioids have previously been implicated in the pathophysiology of spinal cord injury, but the specific opioid(s) involved has not been determined. Here we report that dynorphin administered intrathecally causes dose-related, partially reversible, hindlimb paralysis in the unanesthetized rat. Other opioids, including mu-selective and delta-selective synthetic enkephalins or beta-endorphin, failed to induce motor dysfunction. These findings suggest that dynorphin or dynorphin-related peptides may play a role in spinal cord injury.

Topics: Animals; Dynorphins; Endorphins; Paraplegia; Rats; Rats, Inbred Strains; Receptors, Opioid